Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

dechra regulatory b.v. - phenobarbitalum inn - tafla - 100 mg

Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

dechra regulatory b.v. - phenobarbitalum inn - tafla - 25 mg

Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - clindamycinum fosfat - stungulyf, lausn - 150 mg/ml

Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

santen oy* - pilocarpini chloridum nfn; timololum maleat - augndropar, lausn í stakskammtaíláti - 5 mg + 40 mg/ml

Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

santen oy* - timololum maleat - augnhlaup í stakskammtaíláti - 1 mg/g

Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - bisoprololum fúmarat - filmuhúðuð tafla - 5 mg

Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - bisoprololum fúmarat - filmuhúðuð tafla - 10 mg

Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

glenwood gmbh pharmazeutische erzeugnisse - dipyridamolum inn - húðuð tafla - 100 mg

Kesatuan Eropah - Iceland - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamíð - blöðruhálskirtli - innkirtla meðferð - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

hameln pharma gmbh - dexamethasonum natríumfosfat - stungulyf, lausn - 4 mg/ml